Is Apolipoprotein E a new biomarker for DDD and C3GN?
NSMC Intern Dr Jasmine Sethi decodes the recent study visually
Shedding Light on the Dense Matter of C3 Glomerulopathy
Healing, Hype, or Harm: The NefIgArd trial
The NeflgArd Part B Visual Abstract
Does targeted-release formulation of Budesonide improve kidney function in primary IgA Nephropathy? Check out the VA by NSMC Intern Anant Pilawan on NefIgArd part B trial
PRAECISely Predicting Preeclampsia
PRAECIS - Visual Abstract
NSMC Intern Elba Medina creates a crisp VA for the PRAECIS trial.
Also, we have some bonus VAs this time created for NephMadness by our VA editor Divya Bajpai!
Global disparities in kidney disease burden and care - Visual Abstract
The Worldwide Shadow of Kidney Disease
The PROTECT-V platform - RENALISM no more?
Dialysis dreams and sleepless realities: the SLEEP-HD trial
The SLEEP-HD Visual Abstract
Check out the dreamy Visual Abstract by Cristina Popa
Any sleep potion for insomnia in patients on hemodialysis?
🤔 Trainee Love and Breakup Letters to NephSIM
Trainee Love and Breakup Letters to NephSIM: A Free, Mobile-Optimized, Nephrology Teaching Tool (Fattah, CJASN 2023)
🤔 Does BP lowering matter for the kidneys after all?
Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes (Ku, JASN 2023)
🤔 AT receptor action and dementia
Association of New Use of Antihypertensives That Stimulate vs Inhibit Type 2 and 4 Angiotensin II Receptors With Dementia Among Medicare Beneficiaries (Marcum, JAMA Open Network 2022)
🤔 Starting ARB in hospitalized COVID, an RCT
Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial (Jardine, The BMJ 2022)
🤔 Empagliflozin in acute decompensated heart failure
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (Voors, Nature Medicine 2023)
🤔 Timing of BP medications, aka chronotherapy
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial (Mackenzie, The Lancet 2023)
🤔 Spooky sodium, not so spooky
Tissue sodium excess is not hypertonic and reflects extracellular volume expansion (Rossitto, Nature Communications 2020)
🤔 Coffee and the kidneys
CYP1A2 Genetic Variation, Coffee Intake, and Kidney Dysfunction (Mahdavi, JAMA Network Open 2023)
🤔 Improving decision making in CKD
Effectiveness of an Intervention to Improve Decision Making for Older Patients With Advanced Chronic Kidney Disease (Ladin, Annals Int Med 2023)